|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: PRPSAP2 |
Gene summary for PRPSAP2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | PRPSAP2 | Gene ID | 5636 |
| Gene name | phosphoribosyl pyrophosphate synthetase associated protein 2 | |
| Gene Alias | PAP41 | |
| Cytomap | 17p11.2 | |
| Gene Type | protein-coding | GO ID | GO:0006015 | UniProtAcc | O60256 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 5636 | PRPSAP2 | LZE4T | Human | Esophagus | ESCC | 6.36e-25 | 7.31e-01 | 0.0811 |
| 5636 | PRPSAP2 | LZE7T | Human | Esophagus | ESCC | 3.16e-09 | 4.46e-01 | 0.0667 |
| 5636 | PRPSAP2 | LZE22T | Human | Esophagus | ESCC | 4.21e-05 | 3.02e-01 | 0.068 |
| 5636 | PRPSAP2 | LZE24T | Human | Esophagus | ESCC | 3.85e-24 | 7.14e-01 | 0.0596 |
| 5636 | PRPSAP2 | LZE21T | Human | Esophagus | ESCC | 1.20e-04 | 2.84e-01 | 0.0655 |
| 5636 | PRPSAP2 | LZE6T | Human | Esophagus | ESCC | 8.60e-06 | 3.50e-01 | 0.0845 |
| 5636 | PRPSAP2 | P1T-E | Human | Esophagus | ESCC | 3.34e-07 | 4.03e-01 | 0.0875 |
| 5636 | PRPSAP2 | P2T-E | Human | Esophagus | ESCC | 1.74e-42 | 8.56e-01 | 0.1177 |
| 5636 | PRPSAP2 | P4T-E | Human | Esophagus | ESCC | 1.38e-46 | 9.99e-01 | 0.1323 |
| 5636 | PRPSAP2 | P5T-E | Human | Esophagus | ESCC | 2.59e-14 | 1.55e-01 | 0.1327 |
| 5636 | PRPSAP2 | P8T-E | Human | Esophagus | ESCC | 3.79e-21 | 4.29e-01 | 0.0889 |
| 5636 | PRPSAP2 | P9T-E | Human | Esophagus | ESCC | 6.53e-19 | 4.29e-01 | 0.1131 |
| 5636 | PRPSAP2 | P10T-E | Human | Esophagus | ESCC | 1.92e-42 | 7.72e-01 | 0.116 |
| 5636 | PRPSAP2 | P11T-E | Human | Esophagus | ESCC | 1.41e-13 | 4.90e-01 | 0.1426 |
| 5636 | PRPSAP2 | P12T-E | Human | Esophagus | ESCC | 6.00e-47 | 9.61e-01 | 0.1122 |
| 5636 | PRPSAP2 | P15T-E | Human | Esophagus | ESCC | 1.54e-22 | 4.48e-01 | 0.1149 |
| 5636 | PRPSAP2 | P16T-E | Human | Esophagus | ESCC | 8.98e-35 | 6.76e-01 | 0.1153 |
| 5636 | PRPSAP2 | P17T-E | Human | Esophagus | ESCC | 5.47e-09 | 4.09e-01 | 0.1278 |
| 5636 | PRPSAP2 | P19T-E | Human | Esophagus | ESCC | 1.77e-04 | 4.31e-01 | 0.1662 |
| 5636 | PRPSAP2 | P20T-E | Human | Esophagus | ESCC | 7.46e-26 | 5.61e-01 | 0.1124 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0006753110 | Esophagus | ESCC | nucleoside phosphate metabolic process | 288/8552 | 497/18723 | 1.80e-08 | 3.50e-07 | 288 |
| GO:0019693111 | Esophagus | ESCC | ribose phosphate metabolic process | 234/8552 | 396/18723 | 4.24e-08 | 7.76e-07 | 234 |
| GO:0009117111 | Esophagus | ESCC | nucleotide metabolic process | 282/8552 | 489/18723 | 4.70e-08 | 8.50e-07 | 282 |
| GO:0072521111 | Esophagus | ESCC | purine-containing compound metabolic process | 238/8552 | 416/18723 | 1.20e-06 | 1.49e-05 | 238 |
| GO:0046390110 | Esophagus | ESCC | ribose phosphate biosynthetic process | 119/8552 | 190/18723 | 1.73e-06 | 2.06e-05 | 119 |
| GO:0006163111 | Esophagus | ESCC | purine nucleotide metabolic process | 226/8552 | 396/18723 | 2.81e-06 | 3.21e-05 | 226 |
| GO:000916516 | Esophagus | ESCC | nucleotide biosynthetic process | 150/8552 | 254/18723 | 1.12e-05 | 1.06e-04 | 150 |
| GO:190129316 | Esophagus | ESCC | nucleoside phosphate biosynthetic process | 151/8552 | 256/18723 | 1.15e-05 | 1.08e-04 | 151 |
| GO:007252217 | Esophagus | ESCC | purine-containing compound biosynthetic process | 120/8552 | 200/18723 | 3.02e-05 | 2.51e-04 | 120 |
| GO:000616417 | Esophagus | ESCC | purine nucleotide biosynthetic process | 113/8552 | 191/18723 | 1.16e-04 | 8.04e-04 | 113 |
| GO:19016574 | Esophagus | ESCC | glycosyl compound metabolic process | 57/8552 | 88/18723 | 2.32e-04 | 1.44e-03 | 57 |
| GO:00091163 | Esophagus | ESCC | nucleoside metabolic process | 39/8552 | 62/18723 | 4.68e-03 | 1.82e-02 | 39 |
| GO:000675318 | Oral cavity | OSCC | nucleoside phosphate metabolic process | 247/7305 | 497/18723 | 6.28e-07 | 8.96e-06 | 247 |
| GO:000911719 | Oral cavity | OSCC | nucleotide metabolic process | 243/7305 | 489/18723 | 7.80e-07 | 1.09e-05 | 243 |
| GO:001969319 | Oral cavity | OSCC | ribose phosphate metabolic process | 199/7305 | 396/18723 | 2.97e-06 | 3.64e-05 | 199 |
| GO:19016573 | Oral cavity | OSCC | glycosyl compound metabolic process | 52/7305 | 88/18723 | 1.06e-04 | 7.84e-04 | 52 |
| GO:007252120 | Oral cavity | OSCC | purine-containing compound metabolic process | 199/7305 | 416/18723 | 1.34e-04 | 9.53e-04 | 199 |
| GO:000616320 | Oral cavity | OSCC | purine nucleotide metabolic process | 188/7305 | 396/18723 | 3.31e-04 | 2.04e-03 | 188 |
| GO:00091162 | Oral cavity | OSCC | nucleoside metabolic process | 37/7305 | 62/18723 | 7.79e-04 | 4.23e-03 | 37 |
| GO:19012938 | Oral cavity | OSCC | nucleoside phosphate biosynthetic process | 125/7305 | 256/18723 | 8.32e-04 | 4.41e-03 | 125 |
| Page: 1 2 3 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| PRPSAP2 | SNV | Missense_Mutation | c.931N>C | p.Glu311Gln | p.E311Q | O60256 | protein_coding | tolerated(0.07) | benign(0.082) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| PRPSAP2 | SNV | Missense_Mutation | c.820N>A | p.Asp274Asn | p.D274N | O60256 | protein_coding | tolerated(0.07) | benign(0.072) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
| PRPSAP2 | SNV | Missense_Mutation | c.182T>C | p.Val61Ala | p.V61A | O60256 | protein_coding | deleterious(0) | possibly_damaging(0.902) | TCGA-C8-A135-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR | |
| PRPSAP2 | deletion | Frame_Shift_Del | novel | c.1066delG | p.Glu356SerfsTer10 | p.E356Sfs*10 | O60256 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD | ||
| PRPSAP2 | SNV | Missense_Mutation | c.949G>C | p.Glu317Gln | p.E317Q | O60256 | protein_coding | tolerated(0.13) | benign(0.115) | TCGA-EK-A3GK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| PRPSAP2 | SNV | Missense_Mutation | rs201454078 | c.1048C>T | p.Arg350Cys | p.R350C | O60256 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AA-3949-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| PRPSAP2 | SNV | Missense_Mutation | c.572N>T | p.Ala191Val | p.A191V | O60256 | protein_coding | deleterious(0.01) | benign(0.044) | TCGA-CM-4743-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Chemotherapy | capecitabine | SD | |
| PRPSAP2 | SNV | Missense_Mutation | novel | c.409N>T | p.Ala137Ser | p.A137S | O60256 | protein_coding | tolerated(0.27) | benign(0.251) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| PRPSAP2 | SNV | Missense_Mutation | rs750128219 | c.236N>T | p.Ser79Leu | p.S79L | O60256 | protein_coding | tolerated(0.16) | possibly_damaging(0.523) | TCGA-AJ-A5DW-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| PRPSAP2 | SNV | Missense_Mutation | c.14C>T | p.Thr5Met | p.T5M | O60256 | protein_coding | deleterious_low_confidence(0.02) | benign(0.09) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |